Wake Forest, NC, United States of America

Robert Toms Jacobs

This inventor holds 24 USPTO granted patents and 6 published patent applications, plus 5 CIPO patents and 10 EPO patents, primarily in Boron Chemistry. Top assignees: Anacor Pharmaceuticals, Inc., Astrazeneca Ab, Bill & Melinda Gates Foundation. Active years: 2002-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert Toms Jacobs. Retrieved from https://idiyas.com/inventor/robert-toms-jacobs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 6)

% Patents Active = 70.8

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 10 (Patent Applications = 14)

Average Co-Inventor Count = 6.4

ph-index = 5

Forward Citations = 146(Granted Patents)

Location History:

Hockessin, DE (US) (2002)
Wilmington, DE (US) (2007)
Research Triangle Park, NC (US) (2008)
Durham, NC (US) (2011)
Wake Forest, NC (US) (2010 - 2023)

Company Filing History:

11 out of 70

Anacor Pharmaceuticals, Inc.

Bill & Melinda Gates Foundation

Aventis Agriculture Limited

patents

6. 2 out of 8,745

US Government as Represented by the Secretary of the Army

where one patent can have more than one assignee

Years Active: 2002-2023

Loading Chart...

Areas of Expertise:

Oxaborole

Boron Compounds

PDE4 Inhibitors

Antiprotozoal Agents

Anti-Inflammatory Agents

Lactams

Small Molecules

Therapeutic Heterocycles

Enantiomerically Enriched

Aryloazol Compounds

Chemical Synthesis

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11691992 - Oxaborole analogs and uses thereof (2023-07-04),

2. 11578087 - Oxaborole esters and uses thereof (2023-02-14),

3. 11559538 - Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors (2023-01-24),

4. 10961261 - Oxaborole analogs and uses thereof (2021-03-30),

5. 10919916 - Boron-containing small molecules (2021-02-16),

6. 10882872 - Oxaborole esters and uses thereof (2021-01-05),

7. 10874679 - Boron-containing small molecules (2020-12-29),

8. 10611781 - Boron-containing small molecules (2020-04-07),

9. 10611780 - Boron-containing small molecules (2020-04-07),

10. 10562921 - Oxaborole esters and uses thereof (2020-02-18),

11. 10301329 - Boron-containing small molecules as antiprotozoal agents (2019-05-28),

12. 9493489 - Boron-containing small molecules as anti-protozoal agents (2016-11-15),

13. 9440994 - Boron containing small molecules as antiprotozoal agents (2016-09-13),

14. 8822689 - Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof (2014-09-02),

15. 8623911 - Boron-containing small molecules as anti-protozoal agent (2014-01-07),

Title: Robert Toms Jacobs: A Collaborative Innovator in Treating Parasitic Diseases

Introduction:

Robert Toms Jacobs, a seasoned inventor hailing from Wake Forest, NC, has made significant contributions to the field of medicine, particularly in treating diseases caused by parasites. With an impressive portfolio of 24 patents, Jacobs has consistently demonstrated his expertise and dedication to developing innovative solutions. This article explores his latest patents, career highlights, and noteworthy collaborations with other inventors.

Latest Patents:

Jacobs' recent patents showcase his commitment to advancing the treatment of diseases caused by parasites, including Chagas disease and African Animal Trypanosomosis. One of his latest patents is "Oxaborole analogs and uses thereof," which describes compounds, compositions, and methods for treating, preventing, and eradicating the pathology associated with parasite-driven diseases.

Additionally, Jacobs' patent entitled "Oxaborole esters and uses thereof" introduces oxaborole ester compounds and compositions that effectively combat diseases associated with parasites. These pioneering inventions underline his profound understanding of the intricacies involved in treating parasitic infections.

Career Highlights:

Throughout his career, Jacobs has worked with renowned biopharmaceutical companies, contributing significantly to their research and development efforts. Notably, he has collaborated with Anacor Pharmaceuticals, Inc. and AstraZeneca AB, leveraging their resources and expertise to bring his inventions to fruition. His association with reputable industry players speaks volumes about his credibility and influence.

Collaborations:

In his quest to develop novel treatment methods, Jacobs has collaborated closely with fellow inventors, including Jacob J Plattner and Yong-Kang Zhang. Their collective efforts have resulted in groundbreaking advancements and propelled the field of parasitic disease treatment forward.

Conclusion:

Robert Toms Jacobs stands as a prominent figure in the field of parasitic disease treatment, with an impressive patent portfolio comprising 24 innovative solutions. His recent patents demonstrate an unwavering commitment to alleviating the burden of diseases caused by parasites, providing a glimmer of hope for countless individuals worldwide. Jacobs' collaborations with esteemed biopharmaceutical companies and fellow inventors underscore his ability to foster fruitful partnerships in pursuit of medical advancement. As he continues to push boundaries and explore new possibilities, we can anticipate even greater contributions from this visionary innovator for the betterment of global healthcare.

Profile summary based on public USPTO records.